INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim announced today that the company』s marketing authorization application (MAA) for the treatment of flares in generalized pustular psoria…
Boehringer Ingelheim announces European Medicines Agency』s filing acceptance and validation of marketing authorization application for spesolimab in generalized pustular psoriasis
INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim announced today that the company』s marketing authorization application (MAA) for the treatment of flares in generalized pustular psoria…